Where I see patients (1)
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
It's All in the Timing.
The New England journal of medicine
Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.
Journal of geriatric oncology
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Tra...
The arm with the largest mean change in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) from baseline to day 90. The Wilcoxon rank-sum test will be used to compare change in FACT-BMT between arms, and thi...
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
The feasibility of completing molecular, genetic, immunophenotypic, and biochemical testing for assignment of therapy will be assessed based on the proportion of patients for whom testing is completed within 7 days of the registra...
Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute My...
Safety of UCART123v1.2 - Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study